Vanta Bioscience Limited (BOM:540729)
India
· Delayed Price · Currency is INR 27.79
+0.50 (1.83%)
At close: Jun 17, 2025
Vanta Bioscience Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2018 - 2019 |
Operating Revenue | 45.77 | 97.23 | 62.76 | 96.87 | 100.38 | 141.43 | Upgrade
|
Other Revenue | 0.1 | - | - | 3.31 | 0.13 | 0.01 | Upgrade
|
| 45.88 | 97.23 | 62.76 | 100.18 | 100.51 | 141.44 | Upgrade
| |
Revenue Growth (YoY) | -55.31% | 54.93% | -37.35% | -0.33% | -28.94% | 13.84% | Upgrade
|
Cost of Revenue | -13.08 | 7.72 | 9.91 | 8.16 | 9.29 | 13.34 | Upgrade
|
Gross Profit | 58.95 | 89.5 | 52.85 | 92.03 | 91.23 | 128.1 | Upgrade
|
Selling, General & Admin | 46.31 | 50.12 | 47.7 | 33.09 | 30.91 | 55.16 | Upgrade
|
Other Operating Expenses | 23.69 | 26.06 | 29.09 | 20.95 | 20.19 | 29.24 | Upgrade
|
Operating Expenses | 116.41 | 121.15 | 103.49 | 67.2 | 63.62 | 96.29 | Upgrade
|
Operating Income | -57.45 | -31.65 | -50.64 | 24.83 | 27.61 | 31.81 | Upgrade
|
Interest Expense | -50.18 | -57.23 | -56.05 | -23.47 | -20.61 | -19.2 | Upgrade
|
Interest & Investment Income | 0.59 | 0.59 | 0.59 | 0.78 | - | - | Upgrade
|
Currency Exchange Gain (Loss) | -0.19 | -0.19 | 0.09 | 0.15 | -0.53 | 0.86 | Upgrade
|
Other Non Operating Income (Expenses) | -0.2 | -0.2 | 3.38 | - | -0.79 | -0.29 | Upgrade
|
EBT Excluding Unusual Items | -107.45 | -88.69 | -102.63 | 2.28 | 5.68 | 13.19 | Upgrade
|
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.23 | Upgrade
|
Gain (Loss) on Sale of Assets | 0.42 | 0.42 | - | - | 0.22 | - | Upgrade
|
Pretax Income | -107.02 | -88.27 | -102.63 | 2.28 | 5.89 | 13.42 | Upgrade
|
Income Tax Expense | -2.44 | -2.2 | 1.82 | 0.94 | 1.41 | 3.29 | Upgrade
|
Earnings From Continuing Operations | -104.58 | -86.06 | -104.45 | 1.35 | 4.48 | 10.13 | Upgrade
|
Minority Interest in Earnings | 66.1 | 62.9 | 39.64 | -0.46 | 0.01 | -0.08 | Upgrade
|
Net Income | -38.48 | -23.16 | -64.81 | 0.88 | 4.5 | 10.05 | Upgrade
|
Net Income to Common | -38.48 | -23.16 | -64.81 | 0.88 | 4.5 | 10.05 | Upgrade
|
Net Income Growth | - | - | - | -80.38% | -55.25% | 44.23% | Upgrade
|
Shares Outstanding (Basic) | 6 | 6 | 6 | 6 | 6 | 6 | Upgrade
|
Shares Outstanding (Diluted) | 6 | 6 | 6 | 6 | 6 | 6 | Upgrade
|
Shares Change (YoY) | -0.06% | - | - | - | - | - | Upgrade
|
EPS (Basic) | -6.10 | -3.67 | -10.27 | 0.14 | 0.71 | 1.59 | Upgrade
|
EPS (Diluted) | -6.10 | -3.67 | -10.27 | 0.14 | 0.71 | 1.59 | Upgrade
|
EPS Growth | - | - | - | -80.38% | -55.21% | 44.55% | Upgrade
|
Free Cash Flow | -42.64 | -7.21 | -293.17 | -119.02 | -152.22 | -50.11 | Upgrade
|
Free Cash Flow Per Share | -6.76 | -1.14 | -46.45 | -18.86 | -24.12 | -7.94 | Upgrade
|
Gross Margin | 128.50% | 92.06% | 84.21% | 91.86% | 90.76% | 90.57% | Upgrade
|
Operating Margin | -125.24% | -32.55% | -80.69% | 24.78% | 27.47% | 22.49% | Upgrade
|
Profit Margin | -83.89% | -23.82% | -103.26% | 0.88% | 4.47% | 7.10% | Upgrade
|
Free Cash Flow Margin | -92.95% | -7.41% | -467.13% | -118.81% | -151.45% | -35.43% | Upgrade
|
EBITDA | -11.05 | 13.32 | -23.94 | 37.99 | 40.12 | 43.7 | Upgrade
|
EBITDA Margin | -24.09% | 13.70% | -38.14% | 37.92% | 39.92% | 30.90% | Upgrade
|
D&A For EBITDA | 46.4 | 44.97 | 26.7 | 13.16 | 12.51 | 11.89 | Upgrade
|
EBIT | -57.45 | -31.65 | -50.64 | 24.83 | 27.61 | 31.81 | Upgrade
|
EBIT Margin | -125.24% | -32.55% | -80.69% | 24.78% | 27.47% | 22.49% | Upgrade
|
Effective Tax Rate | - | - | - | 41.03% | 23.91% | 24.52% | Upgrade
|
Revenue as Reported | 46.94 | 98.29 | 69.63 | 101.11 | 100.73 | 142.53 | Upgrade
|
Advertising Expenses | - | - | - | 0.03 | 0.12 | 0.17 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.